Use the arrow keys to choose a result, Enter to open it, and Escape to close.
Find a compound, understand its evidence, or learn the chemistry behind it. Start with a clear explanation and follow the sources.
Educational content. No personal medical advice or instructions for human use.
Each letter represents an amino acid residue. Their order describes the sequence; it does not tell you what the peptide will do.
GASLPKEG is an illustrative sequence, not a featured compound.
Try the sequence playgroundSearch names and aliases, compare structures, and see what each profile actually documents.
Open the encyclopedia →Learn peptide basics, how to read research and what an analytical certificate can tell you.
Explore the guides →Explore sequences, estimate unmodified mass and check concentration arithmetic with stated limits.
Use the learning tools →Follow the primary sources
See the material tested, the study design and the findings alongside the limits. Start with these selected evidence briefs.
A small uncontrolled knee-pain report and a two-person safety pilot leave human efficacy and longer-term safety unresolved. The selected rat comparison did not show a significant BPC-157 advantage on tendon failure load.
Read the brief: BPC-157 →The defined fragment has laboratory/metabolism evidence; the rat tendon result concerns incompletely characterized TB-500-labelled material. A human eye trial studied full-length thymosin β4, so it cannot validate the fragment or injectable TB-500.
Read the brief: TB-500 →Three randomized placebo-controlled trials address different questions: weight change, cardiovascular events and a kidney/cardiovascular composite. Interpret each result with its eligibility criteria, analysis population, follow-up and treatment limitations.
Read the brief: Semaglutide →SURPASS-2 measured glycemic change in type 2 diabetes; SURMOUNT-1 measured weight change without diabetes. SURMOUNT-4 tested continuation versus withdrawal after a tolerated lead-in. Different populations, comparators and time origins prevent a ranking across these trials.
Read the brief: Tirzepatide →The phase 3 reports measured weight change with and without type 2 diabetes, or HbA1c change on diet and exercise alone. The liver report reused a subset of an earlier obesity trial. Different populations, endpoints and estimands prevent a ranking across these trials; imaging liver-fat reduction does not establish clinical liver outcomes.
Read the brief: Retatrutide →An ulcer-gel report favored area closure, while a small post-laser trial found no significant objective difference. A cell study compared bound/free forms. These selected studies leave systemic/injectable efficacy and safety unestablished; missing clinical methods limit confidence.
Read the brief: GHK-Cu →Prepared by Peptides Codex. Independent review by a qualified subject specialist is pending.
Compare molecular identity, research findings and the limits of the evidence.
Studied in rodent models of tendon, muscle, ligament, gut and skin injury; proposed angiogenic and nitric-oxide-related mechanisms
N-acetylated 7-residue fragment of thymosin β4's actin-binding motif; in-vitro research, with rodent tendon findings for vendor-labelled material of uncharacterized sequence
Long-acting GLP-1 receptor agonist
Dual GIP and GLP-1 receptor agonist
GIP / GLP-1 / glucagon receptor triple agonist (investigational, phase 3)
Copper-binding tripeptide studied in skin biology
A beginner-friendly primer on what peptides are, how they differ from proteins and SARMs, approved medicines vs research materials, and how to learn responsibly.
Side-by-side educational comparison of BPC-157 and TB-500—sequences, research themes, stacking discussions, and evidence limits.
From endogenous GLP-1 to dual and triple agonists—an educational map of incretin peptide science and metabolic drug design.
Understand HPLC purity, mass spectrometry identity, net peptide content, TFA salts, and red flags on research peptide COAs.
A cell study, an animal experiment, a clinical trial and a regulator's decision answer different questions. Our sources identify their scope, and recorded review dates are separate from registry updates.